四川長虹(600839.SH):擬在香港新設子公司
格隆匯2月20日丨四川長虹(600839.SH)公佈,爲有效應對海外業務制裁風險,會議同意公司與公司下屬子公司安健控股有限公司(簡稱“安健控股”)以自有資金共同出資在香港新設子公司,新設子公司的公司名稱爲恆聯貿易有限公司,英文名爲StableLinkTradingLtd.(名稱暫定,以最終登記名稱爲準);註冊地址:香港特別行政區(由祕書公司提供地址掛靠,以最終登記爲準);註冊資本:1,000萬美元;股權結構:公司認繳出資800萬美元,持股比例80%,安健控股認繳出資200萬美元,持股比例20%。同意授權公司經營管理層組織實施相關事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.